SAB Biotherapeutics, Inc.
SABS
$2.23
$0.3518.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -62.39% | -- | 207.72% | 62.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -62.39% | -- | 207.72% | 62.55% |
| Cost of Revenue | -6.00% | 78.05% | 94.81% | 86.29% | 79.60% |
| Gross Profit | -6.33% | -88.78% | -184.50% | -83.39% | -82.10% |
| SG&A Expenses | -25.65% | -83.39% | 35.32% | 25.61% | 21.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.67% | -47.22% | 71.61% | 59.47% | 54.52% |
| Operating Income | 5.43% | 46.97% | -112.47% | -57.52% | -53.89% |
| Income Before Tax | -3.40% | 50.15% | -102.84% | -6.61% | 31.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.40% | 50.15% | -102.84% | -6.61% | 31.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.40% | 50.15% | -102.84% | -6.61% | 31.66% |
| EBIT | 5.43% | 46.97% | -112.47% | -57.52% | -53.89% |
| EBITDA | -6.25% | 48.56% | -138.44% | -63.78% | -45.18% |
| EPS Basic | -2.85% | 63.73% | -14.80% | 41.92% | 62.73% |
| Normalized Basic EPS | -2.85% | 63.65% | -14.81% | 41.92% | 62.73% |
| EPS Diluted | -2.85% | 63.73% | -14.80% | 41.92% | 62.73% |
| Normalized Diluted EPS | -2.85% | 63.65% | -14.81% | 41.92% | 62.73% |
| Average Basic Shares Outstanding | 0.54% | 37.43% | 76.68% | 83.55% | 83.38% |
| Average Diluted Shares Outstanding | 0.54% | 37.43% | 76.68% | 83.55% | 83.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |